Journal of Nephrology (2020) 33:653–655
https://doi.org/10.1007/s40620-020-00779-0
NEPHROLOGY PICTURES
Smile! (Life will be better)
Vittoria Esposito1 · Giuseppe Sileno1 · Silvio Abati2 · Marco Colucci1 · Massimo Torreggiani1 · Fabrizio Grosjean3 ·
Ciro Esposito1,4
Received: 20 May 2020 / Accepted: 6 June 2020 / Published online: 17 June 2020
© The Author(s) 2020
Keywords Cyclosporine · Advere events · Gingival · Kidney transplant
Z.G. 57 years-old, male was referred to our out patient
clinic for follow up, 6 years after a kidney transplant. His
past medical history was remarkable for polycystic kidney
disease (ADPKD) and arterial hypertension treated with
calcium channel blockers. In 1997 he underwent aneurysmectomy of the anterior communicating artery. In 2001 he
developed dilated cardiomyopathy with 30% EF and progressive reduction of renal function. In 2003 the patient
started extracorporeal dialysis with improvement of clinical and hemodynamic conditions. In 2004 he underwent
left nephrectomy. In 2007 PTCA and AVI stenting and ICD
placement. In 2010 kidney transplantation associated with
right nephrectomy. After the surgery immediate recovery of
urinary output. A triple immunosuppressive regimen with
cyclosporine, mycophenolate and prednisone was started.
An increase of CMV-DNA copies in the early post transplant period was treated successfully with valgancyclovir.
Since 2013 substantially stable kidney function with serum
creatinine around 1.6–1.7 mg/dl and absence of proteinuria.
Cardiological consults performed in the post transplantation period showed stability of the cardiac conditions with
preserved cardiac function. A cardiac ultrasound performed
in 2016 showed left ventricular hypertrophy EF of 56% and
PAPs 35 mmHg. In September 2016 the patient was referred
for follow-up to our Nephrology Unit. At the first visit the
patient presented with severe gingival hyperplasia (Fig. 1a,
* Ciro Esposito
ciro.esposito@icsmaugeri.it
1
Nephrology and Dialysis Unit, ICS Maugeri SpA SB, Pavia,
Italy
2
Dental Clinic, IRCCS San Raffaele, Segrate, Italy
3
Nephrology and Dialysis Unit, Policlinico San Matteo, Pavia,
Italy
4
Nephrology and Dialysis Unit, University of Pavia, Via
Maugeri 10, 27100 Pavia, Italy
b) complaining of growing difficulties in eating and inability
to perform oral hygiene. He felt miserable for his appearance that made him uneasy to relate with others. The patient
reported frequent dental interventions in order to solve the
problem.
What is gingival overgrowth and which are
the main predisposing factors?
Gingival overgrowth mainly affecting the anterior teeth,
more pronounced on the labial surface (Fig. 1a) but also
present on the anterior palate (Fig. 1b) is an adverse effect
of the systemic administration of certain drugs such as phenytoin, calcium channel blockers and cyclosporine A [1]. Its
incidence was particularly elevated two decades ago when
cyclosporine was the most common immunosuppressive
drug prescribed to kidney transplanted recipients to prevent
acute rejection, with incidence rates ranging from 13 to 84%.
The effect of cyclosporine on gingival growth is amplified
by the association with calcium channel blockers [2]. Age,
gender, smoking habits, age at transplantation, duration of
therapy and CyA dosage and poor oral hygiene represent
risk factors for the development and the severity of gingival
overgrowth.
What are the mechanisms leading
to cyclosporine‑induced gingival
overgrowth?
Gingival hypertrophy is histologically characterized by an
increase in matrix deposition with proliferation of fibroblasts and inflammatory cells. It is well known that cyclosporine stimulates the deposition of matrix components [3].
At gum level it appears to promote gingival fibroblast IL-6
13
Vol.:(0123456789)
654
Journal of Nephrology (2020) 33:653–655
Fig. 1 Cyclosporine-induced gingival overgrowth in a kidney transplant patient. a Gingival labial surface; b anterior palate; c scalpel gingivectomy; d dental plaques; e regression of gingival overgrowth after cyclosporine withdrawal
synthesis which increases collagen production. The susceptibility to gingival overgrowth seems to be increased by
polymorphisms of MDR1 gene, encoding for P-glycoprotein.
P-glycoprotein is part of ABC family of transporters and
is expressed in the ducts of salivary gland having a role in
excretion of certain drugs. A mutation of the MDR1 gene
could reduce the excretion of cyclosporine, increasing its
salivary concentration and its effects on gingival cells [4].
Poor oral hygiene with dental plaques (Fig. 1d, arrows) may
contribute to gingival overgrowth triggering inflammatory
changes and, through the release of mediators of inflammation, favor gingival growth.
assessed since they may not be free from risks, especially
infections. Furthermore relapses are not uncommon. The
best therapeutic option is the withdrawal of the causative
agent. Fortunately we have now alternative antirejection and
antyhypertensive drugs for kidney transplant recipients. Tacrolimus causes fewer side effects than cyclosporine and as
shown in our patient (Fig. 1e), it took just a few months
after shifting from cyclosporine to tacrolimus and stopping
nifedipine, for the gingival overgrowth to almost completely
regress. Our patient’s renal function remains stable 4 years
after shifting to tacrolimus.
Gingival overgrowth management
Conclusions
Oral hygiene is the first of several approaches proposed for
the management of gingival overgrowth [5]. Surgical treatment including scalpel gingivectomy as shown in Fig. 1c,
flap surgery and laser gingivectomy should be carefully
Beyond the smile, gingival overgrowth interferes with dental occlusion and speech. Furthermore it also makes oral
hygiene very complicated due to frequent bleeding and pain.
It makes the quality of life and relationships of the affected
13
Journal of Nephrology (2020) 33:653–655
patients very poor. Kidney transplant is the best treatment
for end stage kidney disease. With the kidney transplant program we want to give our patients an almost normal kidney
function allowing them a better quality of life but we also
want them to enjoy little things every day and smile.
Compliance with ethical standards
Conflict of interst On behalf of all authors, the corresponding author
states that there is no conflict of interest.
Ethical approval All procedure performed in the present study were in
accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments
or comparable ethical standards.
Informed consent Informed consent was obtained from the patient.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long
as you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons licence, and indicate if changes
were made. The images or other third party material in this article are
included in the article’s Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in
the article’s Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will
655
need to obtain permission directly from the copyright holder. To view a
copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. Kataoka M, Kido J-i, Shinohara Y, Nagata T (2002) Drug-induced
gingival overgrowth-a review. Biol Pharm Bull 28:1817–1821
2. Nanda T, Singh B, Sharma P, Singh Arora K (2019) Cyclosporine
A and amlodipine induced gingival overgrowth in a kidney transplant recipient: case presentation with literature review. BMJ Case
Rep 12:e229587
3. Esposito C, Foschi A, Parrilla B, Cornacchia F, Fasoli G, Plati
AR, De Mauri A, Mazzullo T, Scudellaro R, Dal Canton A (2004)
Effect of calcineurin inhibitors on extracellular matrix turnover in
isolated human glomeruli. Tranpl Proc 36:695–697
4. De Iudicibus S, Castronovo G, Gigante A, Stocco G, Decorti G, Di
Lenarda R, Bartoli F (2008) Role of MDR1 gene polymorphisms
in gingival overgrowth induced by cyclosporine in transplant
patients. J Periodont Res 43:665–672
5. Chang CC, Lin TM, Chan CP, Pan WL (2018) Nonsurgical periodontal treatment and prosthetic rehabilitation of a renal transplant patient with gingival enlargement: a case report with two
years follow-up. BMC Oral Health 18:140
Publisher’s Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
13